|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A recurrent chromosomal abnormality in acute myeloid leukemia is the reciprocal translocation t(8;21) that fuses RUNX1 and ETO genes.
|
26333776 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Inactivating or dominant-negative mutations in the RUNX1 gene have been also identified in pedigrees of familial platelet disorders with a variable propensity to develop acute myeloid leukemia (FPD/AML).
|
21725049 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?
|
29025598 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Altered PU.1 function is possibly implicated in leukemogenesis, as PU.1 gene mutations were identified in some patients with acute myeloid leukemia (AML) and as several oncogenic products (AML1-ETO, promyelocytic leukemia-retinoic acid receptor alpha, FMS-like receptor tyrosine kinase 3 internal tandem duplication) are associated with PU.1 downregulation.
|
17361223 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis showed one each of D835 Y, D835 V, and D835 H. Of the three patients carrying FLT3-TKD, two had AML-M3 with one each of L- and V-type PML-RARalpha, and another one had AML-M2 with AML1-ETO.
|
12750701 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recently, we reported that the fusion protein AML1/MDS1/EVI1 (AME), a product of a t(3;21)(q26;q22) associated with chronic myelogenous leukemia and acute myelogenous leukemia, displays a complex pattern of self-interaction.
|
17575132 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We isolated and characterized a novel AML1 (also termed Runx1) fusion transcript from a radiation-associated acute myeloid leukemia with a t(19;21).
|
15203284 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Acquired somatic point mutations in RUNX1/CBFA2/AML1 have recently been described in a subset of patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
|
15613106 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, RUNX1-mutated AML is associated with a complex mutation cluster and is correlated with distinct clinico-pathologic features and inferior prognosis.
|
27137476 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prkch deletion in an Flt3-ITD/Runx1 mutant mouse AML model did not extend survival.
|
28596089 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
|
19357396 |
2009 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, older age was an important risk factor for IR-AML patients undergoing chemotherapy-only; FLT3-ITD, MLL-PTD and RUNX1 mutations were significant risk factors for IR-AML patients who received allo-HSCT.
|
29904089 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
With an incidence of up to 12% in all AML cases, the translocation t(8;21), forming the AML1-ETO fusion gene, is one of the most common genetic aberrations in AML.
|
16294039 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutation of RUNX1 is implicated in various hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia (AML), and previous studies using mouse models disclosed its critical roles in hematopoiesis.
|
24732596 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two supervised methods of analysis were used to identify the 20 best discriminating genes between the following cohorts: acute myelogenous leukemia (AML) versus acute lymphoblastic leukemia (ALL); B-lineage versus T-lineage ALL; newly diagnosed B-lineage standard-risk versus high-risk ALL; and B-lineage leukemia harboring the TEL-AML 1 fusion versus patients without a molecularly characterized translocation.
|
12374679 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Disruption of Runx1/AML1 subnuclear localization, either by a single amino acid substitution or by a chromosomal translocation [e.g., t(8;21)], is linked to the etiology of acute myeloid leukemia (AML).
|
19826043 |
2009 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This is the second cryptic RUNX1 translocation in hematologic malignancies and the first in AML.
|
16357831 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Both TEL and AML-1 are involved in several myeloid leukemia-associated translocations with AML-1/CBF beta being altered in 20-30% of de novo acute myeloid leukemia (AML) cases.
|
8609706 |
1995 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The RUNX1/ETO (RE) fusion protein, which originates from the t(8;21) chromosomal rearrangement, is one of the most frequent translocation products found in de novo acute myeloid leukemia (AML).
|
24897507 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Among them CBFA2T2, a member of the "ETO" family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
|
20958258 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The chromosomal translocation t(8;21), fusing the DNA binding domain of AML1 to the corepressor eight-twenty-one (ETO), is frequently associated with acute myeloid leukemia and generates the AML1/ETO (AE) fusion protein.
|
28360416 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequency of RUNX1 point mutations was about 4% in a group of children with de novo AML aged 0-14 years diagnosed during the period of 1998-2009.
|
21294243 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Based on these 293 genes, the cyclooxygenase (COX), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways were predicted to be specifically activated in AMLs with <i>RUNX1-RUNX1T1</i> fusion.
|
30959925 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Second, with the same reporter system we assessed how these temporal dynamics are affected by the t(8;21)(q22;q22) acute myelogenous leukemia mutant RUNX1-MTG8 (RM8) in single 32D-RM8<sup>miR-ON-221</sup> myeloblasts.
|
29156756 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These features make this an attractive method to prospectively evaluate the prognostic value of AML1/ETO fusion transcript quantitation in a larger patient population with t(8;21)(q22;q22) AML in CR.
|
9737700 |
1998 |